Bleakley Financial Group LLC grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 19.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 431,602 shares of the company’s stock after buying an additional 68,844 shares during the quarter. Bleakley Financial Group LLC’s holdings in Takeda Pharmaceutical were worth $7,993,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in TAK. JPMorgan Chase & Co. increased its position in shares of Takeda Pharmaceutical by 37.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock valued at $3,624,000 after purchasing an additional 67,770 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth $998,000. Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter worth $351,000. Assetmark Inc. grew its stake in shares of Takeda Pharmaceutical by 27.7% during the fourth quarter. Assetmark Inc. now owns 156,120 shares of the company’s stock worth $2,434,000 after purchasing an additional 33,902 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in shares of Takeda Pharmaceutical by 0.6% during the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock worth $210,259,000 after purchasing an additional 82,643 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
TAK has been the topic of a number of analyst reports. Wall Street Zen cut Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Finally, Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.
Takeda Pharmaceutical Price Performance
Shares of NYSE:TAK opened at $16.41 on Wednesday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The firm has a market capitalization of $52.24 billion, a P/E ratio of 42.09 and a beta of -0.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. The company’s fifty day moving average price is $16.11 and its 200 day moving average price is $16.96.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. As a group, sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.12 earnings per share for the current fiscal year.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
